Génexpresszió mérésén alapuló multigénes prognosztikai és prediktív elo″ rejelzés emlo″tumorokban

Zsófia Pénzváltó, Zsuzsanna Mihály, Balázs Gyorffy

Research output: Review article

2 Citations (Scopus)


Patient tailored therapy will serve the fundamentals of future cancer treatment. For this it will be imperative to characterize the tumor and to acquire precise predictive and prognostic information. We can achieve this by using not only monogenic (like ER, PR, HER-2, Ki-67) but also multigene assays, which can provide answers to several diagnostic questions simultaneously. We present a summary of currently available RT-PCR and microarray based multigene tests including MammaPrint, Oncotype DX, BLN Assay, Theros Breast Cancer Index SM, MapQuant DX, ARUP Breast Bioclassifier, Celera Metastatic Score, eXagen BCtm, Invasive Gene Signature, Wound Response Indicator and Mammostrat. Two of these (Oncotype DX and MammaPrint) are already incorporated in several diagnostic protocols. However, multiple unsolved issues deteriorate the value of these tests: generally the validation is poor, the gene sets do not confirm each other, the associated costs are high and the necessary bioinformatics is highly complex.

Translated title of the contributionGene expression based multigene prognostic and predictive tests in breast cancer
Original languageHungarian
Pages (from-to)351-359
Number of pages9
JournalMagyar onkologia
Issue number4
Publication statusPublished - dec. 1 2009


  • Breast cancer
  • Microarray
  • Multigene assay
  • Prediction
  • Prognosis

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'Génexpresszió mérésén alapuló multigénes prognosztikai és prediktív elo″ rejelzés emlo″tumorokban'. Together they form a unique fingerprint.

  • Cite this